Evidence map›Paper›PMID 38024559›Full record

ArticleJID innovations : skin science from molecules to population health2023

Cutaneous and Noncutaneous Adverse Effects in Patients with Advanced Melanoma Receiving Immunotherapy.

Howa Yeung, Krittin J Supapannachart, Sandy Francois, Colin H Adler, Ragini R Kudchadkar, David H Lawson, Melinda L Yushak, Afreen I Shariff, Suephy C Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JID innovations : skin science from molecules to population health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Howa YeungDepartment of Dermatology, Emory University School of Medicine, Atlanta, Georgia, USA.
Krittin J SupapannachartDepartment of Dermatology, University of California San Francisco, San Francisco, California, USA.
Sandy FrancoisDepartment of Dermatology, Emory University School of Medicine, Atlanta, Georgia, USA.
Colin H AdlerDepartment of Dermatology, Emory University School of Medicine, Atlanta, Georgia, USA.
Ragini R KudchadkarDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.
David H LawsonDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.
Melinda L YushakDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.
Afreen I ShariffDivision of Endocrinology, Diabetes, and Metabolism, Duke University School of Medicine, Durham, North Carolina, USA.
Suephy C ChenDepartment of Dermatology, Duke University School of Medicine, Durham, North Carolina, USA.
Emory University · USDuke University · USUniversity of California, San Francisco · US

Funding

Epidemiology, impact, and experience of acne in transgender personsK23AR075888 · NIAMS · EMORY UNIVERSITY · PI YEUNG, HOWA · 2020 to 2024
$789k
NIAMS NIH HHS K23 AR075888NIAMS NIH HHS L30 AR076081
6 · The paper itself

Abstract

Relationships between cutaneous adverse effects (CAEs) and noncutaneous adverse effects (NCAEs) of melanoma immunotherapy may help identify patterns tied to distinct immunologic pathways. The objective of this study was to determine the associations between CAEs and NCAEs among patients with stages III-IV melanoma receiving immunotherapy and who were enrolled in a prospective cohort. Electronic medical record data were abstracted from the first immunotherapy infusion until 1 year later. CAEs were rash or itch. NCAEs were symptoms and/or laboratory abnormalities documented as immunotherapy related. NCAE onset and time to NCAE were compared between participants with and without CAEs using ORs and Wilcoxon rank sum tests. Of 34 participants, 11 (32.4%) developed no adverse effects, 7 (20.1%) developed CAEs only, 3 (8.8%) developed NCAEs only, and 13 (38.2%) developed both CAEs and NCAEs. After adjustment for age, sex, and immunotherapy regimen, CAE was associated with higher odds of NCAE development (OR = 9.72; 95% confidence interval = 1.2-76.8). Median NCAE onset was 63 days in those with CAEs and 168 days in those without CAEs (

Identifiers

PMID38024559
PMCPMC10661470
OpenAlexW4386775929

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.